Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Receiving treatment within the first month of life could protect children for at least three years, a study suggests.

To find out what may be behind these numbers, Dr. Ann Khalsa, a clinician at the Valleywise Health McDowell Clinic spoke with ...

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

The Midwest AIDS Training and Education Center’s funding will be cut completely in the current budget proposal for fiscal ...

HIV antivirals may be the key to stopping HTLV-1, a deadly virus with no cure. In a decade-long study, researchers ...

Declining investment in global health surveillance, research, and scientific innovation are happening as the need for vigilance has never been greater, writes Robert C. Gallo.

In a recent landmark study, scientists have unveiled how HIV-1 penetrates the cell's nuclear barrier—a discovery that could reshape antiviral strategies. The research, led by Professor Peijun Zhang, ...

Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in ...

NEARLY 35 U.S. STATES are grappling with outbreaks of vaccine-preventable diseases like measles and whooping cough. A recent American Community Media (ACom) press briefing highlighted concerns from ...